Market capitalization | $14.23b |
Enterprise Value | $16.28b |
P/E (TTM) P/E ratio | 65.05 |
EV/FCF (TTM) EV/FCF | 42.50 |
EV/Sales (TTM) EV/Sales | 6.01 |
P/S ratio (TTM) P/S ratio | 5.26 |
P/B ratio (TTM) P/B ratio | 1.81 |
Dividend yield | 0.24% |
Last dividend (FY24) | $0.28 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
20 Analysts have issued a PerkinElmer forecast:
20 Analysts have issued a PerkinElmer forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,708 2,708 |
5%
5%
|
|
Gross Profit | 1,407 1,407 |
5%
5%
|
|
EBITDA | 797 797 |
10%
10%
|
EBIT (Operating Income) EBIT | 368 368 |
23%
23%
|
Net Profit | 219 219 |
73%
73%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Prahlad Singh |
Employees | 11,500 |
Founded | 1937 |
Website | www.revvity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.